• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    2/1/23 8:06:10 AM ET
    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ANPC alert in real time by email

    Gainers

    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock rose 76.6% to $2.95 during Wednesday's pre-market session. The company's market cap stands at $14.2 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock rose 50.5% to $1.13. The market value of their outstanding shares is at $14.6 million.
    • Chembio Diagnostics (NASDAQ:CEMI) stock increased by 22.22% to $0.44. The market value of their outstanding shares is at $16.1 million.
    • Erytech Pharma (NASDAQ:ERYP) stock increased by 19.98% to $1.08. The market value of their outstanding shares is at $33.4 million.
    • Genetic Technologies (NASDAQ:GENE) shares rose 16.48% to $1.06. The company's market cap stands at $16.3 million.
    • F-star Therapeutics (NASDAQ:FSTX) shares rose 16.05% to $4.77. The market value of their outstanding shares is at $104.8 million.

    Losers

    • Evelo Biosciences (NASDAQ:EVLO) shares declined by 27.9% to $0.75 during Wednesday's pre-market session. The market value of their outstanding shares is at $82.2 million.
    • Invacare (NYSE:IVC) stock decreased by 19.68% to $0.53. The market value of their outstanding shares is at $20.0 million.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares declined by 18.3% to $1.34. The market value of their outstanding shares is at $83.6 million.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares declined by 14.37% to $7.27. The company's market cap stands at $296.5 million.
    • Hillstream BioPharma (NASDAQ:HILS) shares declined by 13.34% to $1.04. The company's market cap stands at $11.9 million.
    • Lucira Health (NASDAQ:LHDX) shares fell 11.09% to $0.37. The company's market cap stands at $14.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANPC
    $CEMI
    $ERYP
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    Taysha Gene Therapies Inc.
    $TSHA
    6/27/2024$5.00Outperform
    BMO Capital Markets
    Taysha Gene Therapies Inc.
    $TSHA
    4/9/2024$9.00Overweight
    Piper Sandler
    Taysha Gene Therapies Inc.
    $TSHA
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    Taysha Gene Therapies Inc.
    $TSHA
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    Taysha Gene Therapies Inc.
    $TSHA
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    F-star Therapeutics Inc.
    $FSTX
    7/15/2022$35.00 → $7.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    SEC Filings

    View All

    SEC Form 8-K filed by Quoin Pharmaceuticals Ltd.

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    3/11/26 4:30:34 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:24:03 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cooper Joseph Patrick

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:21:52 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Culverwell Anthony James

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:20:19 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Large owner Manning Paul B bought $2,062,500 worth of shares (750,000 units at $2.75) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    6/3/25 9:38:27 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

    — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome — ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on d

    3/11/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company's common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement

    3/6/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target

    BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00

    6/27/24 7:52:29 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:46:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $CEMI
    $ERYP
    $EVLO
    Financials

    Live finance-specific insights

    View All

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarter Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent, multi-domain impact of TSHA-102 on activities of daily living at the CNS Annual Meeting TSHA-102

    11/4/25 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

    DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2025, at 8:30 AM Eastern Time. Conference Call DetailsTuesday, November 4, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 800-245-3047International: 203-518-9765Conference ID: TAYSHAWebcast: https://ir.tayshagtx.com

    10/28/25 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care